---
title: "HCM IV Acquisition - Unit | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280996435.md"
datetime: "2026-03-30T10:08:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280996435.md)
  - [en](https://longbridge.com/en/news/280996435.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280996435.md)
generator: "portal-rs"
---

# HCM IV Acquisition - Unit | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -0.01.

EBIT: As of FY2025, the actual value is USD -59.66 K.

The Company is a blank check company and has not commenced any operations or generated any revenues to date, therefore no segmented financial or operational metrics are available for the period from September 5, 2025 (inception) through December 31, 2025.

#### Operational Metrics

-   **Net Loss**: For the period from September 5, 2025 (inception) through December 31, 2025, the Company reported a net loss of - $59,655.
-   **Formation, General, and Administrative Costs**: These costs amounted to $59,655 for the period from September 5, 2025 (inception) through December 31, 2025.
-   **Working Capital Deficit**: As of December 31, 2025, the Company had a working capital deficit of - $170,614.

#### Cash Flow

-   **Net Cash Used in Operating Activities**: For the period from September 5, 2025 (inception) through December 31, 2025, net cash used in operating activities was $0.

#### Unique Metrics and Post-Period Financials

-   **Cash and Liquidity (as of December 31, 2025)**: The Company had no cash as of December 31, 2025.
-   **Trust Account Balance (as of March 19, 2026)**: Approximately $288,156,500.99 was held in the trust account.
-   **IPO Gross Proceeds (February 13, 2026)**: The Initial Public Offering generated gross proceeds of $287,500,000 from 28,750,000 units at $10.00 per unit.
-   **Private Placement Warrants Gross Proceeds (February 13, 2026)**: The sale of 4,666,667 Private Placement Warrants generated gross proceeds of $7,000,000.
-   **Total Funds Placed in Trust Account (February 13, 2026)**: $287,500,000 was placed in the Trust Account following the IPO and Private Placement Warrants sale.
-   **Total Transaction Costs**: These costs amounted to $19,591,443, comprising $5,000,000 in cash underwriting fees, $13,687,500 in deferred underwriting fees, and $903,943 in other offering costs.
-   **Promissory Note Repayment**: A promissory note for $371,062 from the Sponsor was fully paid on February 17, 2026, after the IPO closing.

#### Outlook / Guidance

The Company does not expect to generate any operating revenues until after the completion of its initial Business Combination. It anticipates generating non-operating income from interest and/or dividend income on investments held in the Trust Account. The Company expects to incur ongoing expenses as a public company and for due diligence related to a Business Combination.

### Related Stocks

- [HACQU.US](https://longbridge.com/en/quote/HACQU.US.md)

## Related News & Research

- [Stockholder Alert: Robbins LLP Informs Investors of the AEVEX Corp. Class Action](https://longbridge.com/en/news/296658829.md)
- [Tenon Medical (TNON) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296543508.md)
- [AMLX stock clocks best day ever after positive trial data, launches $350M offering](https://longbridge.com/en/news/296273366.md)
- [Serbia Current Account Deficit Largest in 6 Months](https://longbridge.com/en/news/296431805.md)
- [PDS Biotechnology Says Lars Boesgaard To Resign As CFO Effective September 12](https://longbridge.com/en/news/296400297.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**